Hazard Hub
New safety information Recalls in Canada
39 recalls involving new safety information — most are other recalls. Newest first, updated daily from government open data.
Showing 1–30 of 39
TZIELD (teplizumab) and the Risk of Viral Reactivation
New safety information - Adverse reaction - Product safety
View recall details →
TAVNEOS (avacopan) and Health Canada’s Review of Data Integrity Concerns
New safety information - Product safety
View recall details →
ALECENSARO (alectinib) and the Risk of Severe Hypertriglyceridemia
New safety information - Product safety - Adverse reaction
View recall details →
IXCHIQ (chikungunya vaccine, live, attenuated) and the Risk of Serious Adverse Reactions in Medically Frail Individuals 65 Years of Age and Older
New safety information - Product safety - Adverse reaction
View recall details →
Important Safety Information on Yescarta (axicabtagene ciloleucel) and the Risk of Cerebral Edema in Primary Mediastinal B Cell Lymphoma (PMBCL)
New safety information
View recall details →
ITOVEBI (inavolisib) and the Risk of Life-Threatening Ketoacidosis
New safety information - Labelling
View recall details →
Important Safety Information on CRYSVITA (burosumab) and the Risk of Severe Hypercalcemia in Patients with Tertiary Hyperparathyroidism
New safety information - Product safety
View recall details →
Important Safety Information on COPAXONE (glatiramer acetate) and the Risk of Anaphylactic Reactions Which May Occur at Any Time Following Initiation of Treatment
New safety information - Product safety - Adverse reaction
View recall details →
Risk of anaphylactic reaction associated with glatiramer acetate, used to treat multiple sclerosis
Product safety - New safety information
View recall details →
Incorrect dosing information on the “SAVE ME” instructional card in the Naloxone Take Home Kit by Canadian Hospital Specialties Ltd
New safety information
View recall details →
Important Safety and Efficacy Information on ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) – Market Withdrawal and Continued Restricted Access
New safety information - Product withdrawal
View recall details →
IDHIFA (enasidenib mesylate) – Market Withdrawal and Continued Access
New safety information - Product withdrawal
View recall details →
ISTODAX (romidepsin) – Restricted Access Program
New safety information - Product withdrawal
View recall details →
ZEJULA (niraparib) - Update on the Maintenance Treatment in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in the Second or Later Line Setting
New safety information
View recall details →
RUZURGI (amifampridine) - Authorization Status
New safety information - Product withdrawal
View recall details →
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
New safety information - Product safety - COVID
View recall details →
OCALIVA (obeticholic acid) – New Contraindication for the Treatment of Primary Biliary Cholangitis (PBC)
New safety information
View recall details →
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
New safety information - Product safety
View recall details →
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
New safety information - Product safety - COVID
View recall details →
Magnets in certain Philips Respironics sleep therapy masks may cause serious injury to some individuals
New safety information
View recall details →
ZOLGENSMA (onasemnogene abeparvovec) and Fatal Cases of Acute Liver Failure
New safety information
View recall details →
IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure
New safety information - Product safety
View recall details →
IMVAMUNE Vaccine: Updated Storage Conditions and Shelf Life
New safety information - Product safety
View recall details →
COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine): New Formulation/Presentation for Use in Individuals 12 Years of Age and Older
New safety information
View recall details →
Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omicron BA.2 Subvariant
New safety information - COVID
View recall details →
Updated safety review of breast implants underscores the continuing importance of monitoring for cancer; increased risk with highly textured (macro-textured) implants
New safety information
View recall details →
Anticipated shortage of euthanasia products for animals
New safety information - Product safety
View recall details →
Rapid antigen test kits and potential exposure to hazardous substances
New safety information - Increased risk or new adverse events - COVID
View recall details →
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
New safety information - Product safety
View recall details →
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
Labelling - New safety information - Supply - COVID
View recall details →